FY2027 Earnings Forecast for IOVA Issued By HC Wainwright

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities research analysts at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for Iovance Biotherapeutics in a note issued to investors on Friday, November 8th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of $0.08 per share for the year, up from their previous forecast of $0.05. HC Wainwright currently has a “Buy” rating and a $32.00 price target on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.26) per share.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03. Iovance Biotherapeutics had a negative return on equity of 60.50% and a negative net margin of 451.25%. The company had revenue of $58.56 million during the quarter, compared to analyst estimates of $53.54 million. During the same quarter in the previous year, the company posted ($0.46) earnings per share.

IOVA has been the subject of a number of other research reports. UBS Group started coverage on Iovance Biotherapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $17.00 price target for the company. Piper Sandler cut Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $19.00 to $10.00 in a research report on Monday, July 29th. Finally, StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.33.

Iovance Biotherapeutics Price Performance

Shares of IOVA opened at $9.69 on Monday. The business has a fifty day moving average of $10.15 and a 200 day moving average of $9.78. Iovance Biotherapeutics has a one year low of $3.80 and a one year high of $18.33. The firm has a market capitalization of $2.71 billion, a P/E ratio of -6.50 and a beta of 0.60.

Institutional Trading of Iovance Biotherapeutics

Several institutional investors have recently made changes to their positions in IOVA. ORG Partners LLC purchased a new stake in shares of Iovance Biotherapeutics during the second quarter worth about $32,000. Quest Partners LLC boosted its stake in Iovance Biotherapeutics by 1,237.7% during the second quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 4,629 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in Iovance Biotherapeutics during the second quarter valued at approximately $58,000. Daiwa Securities Group Inc. boosted its stake in Iovance Biotherapeutics by 754.0% during the second quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 7,781 shares during the last quarter. Finally, Abacus Planning Group Inc. bought a new position in Iovance Biotherapeutics during the second quarter valued at approximately $82,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.